Sight Sciences (SGHT) Files For a $100M IPO

Sight Sciences (NASDAQ: SGHT) has filed form S-1 for an IPO of up to $100M.

The company's objective is to develop and market products for use in new eyecare treatment paradigms and to create an interventional mindset in eyecare whereby their products may be used in procedures which supplant conventional outdated approaches. They believe current eyecare treatment models rely heavily on prescription medications, symptom relief, or either flawed or highly invasive, later-stage procedural interventions and fail to adequately address the true underlying cause of disease.

Morgan Stanley, BofA Securities, Citigroup and Piper Sandler will serve as underwriters.

You May Also Be Interested In

• Londian Wason New Energy Tech opens at $26, above IPO price of $22
• Red Cat promotes Mitch McDonald to divisional CEO of UAS unit
• Blue Owl Capital prices $750M senior notes offering at 6.750%